NCT06468358View on ClinicalTrials.gov

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Solid Tumor
Interventions
DRUG

LB1410

anti-PD-1/TIM3 bispecific antibody

DRUG

LB4330

anti-claudin18.2/IL-10 fusion protein

Trial Locations (1)

201114

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai East Hospital

OTHER

lead

L & L Bio Co., Ltd., Ningbo, China

INDUSTRY